AIM Stock Summary and Trading Ideas (Aim Immunotech | AMEX:AIM)

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Aim Immunotech trades on the AMEX stock market under the symbol AIM.

As of April 4, 2025, AIM stock price declined to $0.09 with 2,285,654 million shares trading.

AIM has a beta of 1.41, meaning it tends to be more sensitive to market movements. AIM has a correlation of 0.09 to the broad based SPY ETF.

AIM has a market cap of $6.52 million. This is considered a Sub-Micro Cap stock.

Last quarter Aim Immunotech reported $45,000 in Revenue and -$.10 earnings per share. This met revenue expectation and met earnings estimates .

In the last 3 years, AIM traded as high as $1.38 and as low as $.06.

The top ETF exchange traded funds that AIM belongs to (by Net Assets): VTI, VXF.

AIM has underperformed the market in the last year with a price return of -82.1% while the SPY ETF was flat at -0.1%. AIM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -59.4% and -33.2%, respectively, while the SPY returned -14.4% and -10.4%, respectively.

AIM support price is $.11 and resistance is $.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIM shares will trade within this expected range on the day.